EP1575510A4 - Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation - Google Patents

Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation

Info

Publication number
EP1575510A4
EP1575510A4 EP03785053A EP03785053A EP1575510A4 EP 1575510 A4 EP1575510 A4 EP 1575510A4 EP 03785053 A EP03785053 A EP 03785053A EP 03785053 A EP03785053 A EP 03785053A EP 1575510 A4 EP1575510 A4 EP 1575510A4
Authority
EP
European Patent Office
Prior art keywords
aggregation
compositions
treatment
methods
exhibiting protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03785053A
Other languages
German (de)
French (fr)
Other versions
EP1575510A2 (en
Inventor
Eric B Kmiec
Hetal Parekh-Olmedo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Delaware
Original Assignee
University of Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Delaware filed Critical University of Delaware
Publication of EP1575510A2 publication Critical patent/EP1575510A2/en
Publication of EP1575510A4 publication Critical patent/EP1575510A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
EP03785053A 2002-08-07 2003-08-07 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation Withdrawn EP1575510A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40219802P 2002-08-07 2002-08-07
US402198P 2002-08-07
PCT/US2003/024868 WO2004014306A2 (en) 2002-08-07 2003-08-07 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation

Publications (2)

Publication Number Publication Date
EP1575510A2 EP1575510A2 (en) 2005-09-21
EP1575510A4 true EP1575510A4 (en) 2007-12-26

Family

ID=31715805

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03785053A Withdrawn EP1575510A4 (en) 2002-08-07 2003-08-07 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation

Country Status (10)

Country Link
EP (1) EP1575510A4 (en)
JP (1) JP2006509726A (en)
KR (1) KR20050053607A (en)
CN (1) CN101123993A (en)
AU (1) AU2003259073A1 (en)
CA (1) CA2494908A1 (en)
IL (1) IL166706A0 (en)
NO (1) NO20051159L (en)
NZ (1) NZ538145A (en)
WO (1) WO2004014306A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007139120A1 (en) * 2006-05-30 2009-10-08 国立大学法人大阪大学 Amyloid β clearance promoter
KR100982909B1 (en) * 2009-07-08 2010-09-20 고려대학교 산학협력단 Anti-cancer composition containing an ataxin-1 protein or a polynucleotide encoding ataxin-1 and a screening method of anti-cancer agents using the same
WO2011015572A1 (en) * 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2019032613A1 (en) * 2017-08-08 2019-02-14 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of protein aggregation
US20220411794A1 (en) 2019-10-23 2022-12-29 Universitaet Wien Rna oligonucleotides for preventing aggregation of proteins
WO2023205579A1 (en) * 2022-04-18 2023-10-26 The Regents Of The University Of California Compositions and methods for disrupting pathological aggregates

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006545A2 (en) * 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
WO1999029891A1 (en) * 1997-12-09 1999-06-17 Arch Development Corporation Methods for identifying factors controlling amyloid protein aggregation
WO2000073501A2 (en) * 1999-06-01 2000-12-07 LASMÉZAS, Corinne, Ida Nucleic acid molecules with specific identification of native prpsc, their production and the use thereof
WO2001023412A2 (en) * 1999-09-27 2001-04-05 Massachusetts Institute Of Technology Methods of screening for agents which inhibit aggregation of polypeptides
WO2002054083A2 (en) * 2001-01-03 2002-07-11 Ortho-Mcneil Pharmaceutical, Inc. Alpha synuclein aggregation assays
WO2002065136A2 (en) * 2001-02-15 2002-08-22 University Of Chicago Yeast screens for agents affecting protein folding
WO2003013437A2 (en) * 2001-08-07 2003-02-20 University Of Delaware Compositions and methods for the prevention and treatment of huntington's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001575A1 (en) * 1996-07-08 1998-01-15 Pioneer Hi-Bred International, Inc. Transformation of zygote, egg or sperm cells and recovery of transformed plants from isolated embryo sacs
US20030060436A1 (en) * 1998-11-05 2003-03-27 Clifford Kent Weber Esq. Treatment of parkinson's disease with oligonucleotides
JPWO2003044197A1 (en) * 2001-11-21 2005-03-24 独立行政法人科学技術振興機構 Huntington's disease gene transcription factor
US20030235823A1 (en) * 2002-06-24 2003-12-25 The University Of Alabama Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006545A2 (en) * 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
WO1999029891A1 (en) * 1997-12-09 1999-06-17 Arch Development Corporation Methods for identifying factors controlling amyloid protein aggregation
WO2000073501A2 (en) * 1999-06-01 2000-12-07 LASMÉZAS, Corinne, Ida Nucleic acid molecules with specific identification of native prpsc, their production and the use thereof
WO2001023412A2 (en) * 1999-09-27 2001-04-05 Massachusetts Institute Of Technology Methods of screening for agents which inhibit aggregation of polypeptides
WO2002054083A2 (en) * 2001-01-03 2002-07-11 Ortho-Mcneil Pharmaceutical, Inc. Alpha synuclein aggregation assays
WO2002065136A2 (en) * 2001-02-15 2002-08-22 University Of Chicago Yeast screens for agents affecting protein folding
WO2003013437A2 (en) * 2001-08-07 2003-02-20 University Of Delaware Compositions and methods for the prevention and treatment of huntington's disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CORDEIRO Y ET AL: "DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 52, 28 December 2001 (2001-12-28), pages 49400 - 49409, XP002196440, ISSN: 0021-9258 *
KHOSHNAN ALI ET AL: "Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 2, 22 January 2002 (2002-01-22), pages 1002 - 1007, XP002401586, ISSN: 0027-8424 *
LECERF J-M ET AL: "Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 8, 10 April 2001 (2001-04-10), pages 4764 - 4769, XP002323805, ISSN: 0027-8424 *
PROSKE DANIELA ET AL: "Prion-protein-specific aptamer reduces PrPSc formation.", CHEMBIOCHEM : A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY. 2 AUG 2002, vol. 3, no. 8, 2 August 2002 (2002-08-02), pages 717 - 725, XP002401585, ISSN: 1439-4227 *

Also Published As

Publication number Publication date
NO20051159L (en) 2005-04-26
CN101123993A (en) 2008-02-13
EP1575510A2 (en) 2005-09-21
NZ538145A (en) 2008-05-30
AU2003259073A1 (en) 2004-02-25
IL166706A0 (en) 2006-01-15
KR20050053607A (en) 2005-06-08
WO2004014306A3 (en) 2006-05-18
JP2006509726A (en) 2006-03-23
WO2004014306A2 (en) 2004-02-19
CA2494908A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
EP1575480A4 (en) Compositions and methods for the treatment of immune related diseases
EP1578367A4 (en) Compositions and methods for the treatment of immune related diseases
EP1572116A4 (en) Compositions and methods for the treatment of immune related diseases
EP1576137A4 (en) Compositions and methods for the treatment of immune related diseases
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1560593A4 (en) Novel composition and methods for the treatment of immune related diseases
EP1578421A4 (en) Pharmaceutical preparations for treatments of diseases and disorders of the breast
AU2003268531A8 (en) Materials and methods for treatment of allergic diseases
AU2003246102A8 (en) Method of examining allergic disease and drug for treating the same
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1572091A4 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1553912A4 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003216592A8 (en) Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
HK1162127A1 (en) Oil body associated protein compositions and methods as well as use thereof for reducing the risk of cardiovascular disease
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
IL166706A0 (en) Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
EP1578373A4 (en) Novel compositions and methods for the treatment of immune related diseases
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050224

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101ALI20060607BHEP

Ipc: A61K 48/00 20060101AFI20060607BHEP

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

A4 Supplementary search report drawn up and despatched

Effective date: 20070606

DA4 Supplementary search report drawn up and despatched (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20071127

17Q First examination report despatched

Effective date: 20080625

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110301